{
    "clinical_study": {
        "@rank": "102595", 
        "arm_group": {
            "arm_group_label": "Everolimus", 
            "arm_group_type": "Experimental", 
            "description": "Patients who are receiving everolimus in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study that has reached its study objectives, are not progressing on the current study treatment as defined by the parent protocol and are unable to access everolimus treatment outside of a clinical trial will be allowed to enroll."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to collect and assess long-term safety of everolimus in\n      patients who are currently receiving everolimus treatment in a Novartis-sponsored, Oncology\n      CD&MA study that has reached its study objectives, are not progressing on the current study\n      treatment as defined by the parent protocol and are unable to access everolimus treatment\n      outside of a clinical study. Parent studies eligible to participate in the roll-over study\n      will be decided by Novartis. Investigator initiated trials (IITs) will not be included. The\n      primary objective of the parent study must have been reached and the parent study must be in\n      the process of being completed and reported."
        }, 
        "brief_title": "Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.", 
        "completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is currently enrolled in a Novartis-sponsored, CD&MA study receiving\n             everolimus or everolimus plus Sandostatin LAR Depot and has fulfilled all their\n             requirements in the parent study\n\n          -  Patient is currently benefiting from treatment with everolimus, as determined by the\n             guidelines of the parent protocol.\n\n        Exclusion Criteria:\n\n          -  Patient has been permanently discontinued from everolimus study treatment in the\n             parent study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "3", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02017860", 
            "org_study_id": "CRAD001C1X01B"
        }, 
        "intervention": {
            "arm_group_label": "Everolimus", 
            "description": "Everolimus will be provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration", 
            "intervention_name": "Everolimus", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "RAD001, everolimus, roll-over", 
        "lastchanged_date": "February 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Matsuyama", 
                        "country": "Japan", 
                        "state": "Ehime", 
                        "zip": "791-0280"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-city", 
                        "country": "Japan", 
                        "state": "Hokkaido", 
                        "zip": "060-8648"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+81337978748"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Long term safety. Frequency and nature of Adverse Events are to be collected.", 
            "measure": "Number of pariticipants with Adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "From screening period to the end of the study (approximately 6 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02017860"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}